<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505284</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-G000-227</org_study_id>
    <secondary_id>2006-006488-22</secondary_id>
    <nct_id>NCT00505284</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of Perampanel in patients
      with painful diabetic neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group study. This is a
      5-arm, 21-week study comprised of up to a 2-week Screening period, a 15-week Dose-Escalation
      and Maintenance Phase using 4 doses of E2007 (2 mg, 4 mg, 6 mg, and 8 mg) or placebo, and a
      4-week, single-blind placebo Follow-Up Phase. Patients will be randomly assigned to one of
      the five treatment groups. Those patients assigned to receive either 4 mg, 6 mg, or 8 mg
      E2007 will be escalated to the appropriate dose according to an escalation schedule. All
      patients will take four identical-looking tablets on a daily basis for the entire study
      duration for blinding purposes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)</measure>
    <time_frame>Baseline to Week 15/EOT</time_frame>
    <description>Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified baseline observation carried forward (BOCF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score</measure>
    <time_frame>Baseline to Week 15/EOT</time_frame>
    <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 50% Reduction in Pain Score</measure>
    <time_frame>Baseline to Week 15/EOT</time_frame>
    <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Average Pain Scores From Baseline at Each Study Week</measure>
    <time_frame>Baseline, Week 1 to Week 17</time_frame>
    <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Last on-treatment value refers to last 7 days of available diary data while subject was on double-blind study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Average Sleep Interference Scores From Baseline to Week 15/EOT</measure>
    <time_frame>Baseline to Week 15/EOT</time_frame>
    <description>Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for sleep interference (0=pain did not interfere with sleep, to 10=pain completely interfered with sleep [unable to sleep]). Based on modified BOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form - McGill Pain Questionnaire (SF-MPQ) From Baseline to Week 15/EOT</measure>
    <time_frame>Baseline and Week 15/EOT</time_frame>
    <description>SF-MPQ sensory score = sum of intensity scores for descriptors 1-11 (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting). Each descriptor scored as 0=none, 1=mild, 2=moderate, or 3=severe. Range of possible sensory scores, 0 to 33, with a score of 33 being the most severe intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Patient Global Impression of Change (PGIC) at Week 15/EOT</measure>
    <time_frame>Week 15/EOT</time_frame>
    <description>At the EOT (Visit 7) or Early Withdrawal Visit (as appropriate), the subject assessed his/her status compared to how they felt before entering the study. This assessment included an evaluation of pain frequency and intensity, the occurrence of AEs, and overall functional status using a 7-point scale where 1=very much improved and 7=very much worse. Using Modified BOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 15/EOT in SF-36 Physical and Mental Component Scores</measure>
    <time_frame>Baseline and Week 15/EOT</time_frame>
    <description>Short Form 36 Health Survey Questionnaire (SF-36) measuring limitations in Physical Components including physical activities, usual role activities (due to physical problems), measuring bodily pain, general health perceptions, and Mental Components including social activities, usual role activities (due to emotional problems), vitality (energy and fatigue. Each of the 8 domains are described by a score ranging from 0 to 100, for a range of total possible scores of 0-400 for physical and 0-400 for mental. Higher scores reflect better subject status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 15/EOT in Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression Subscale Scores</measure>
    <time_frame>Baseline and Week 15/EOT</time_frame>
    <description>HADS anxiety subscale score=sum of scores for 7 anxiety items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse anxiety. Range of possible HADS anxiety subscale scores, 0 to 21. HADS depression subscale score=sum of scores for 7 depression items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse depression. Range of possible HADS depression subscale scores, 0 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal Due to Treatment Failure During Double-Blind Dosing Period</measure>
    <time_frame>Baseline and Week 15</time_frame>
    <description>Based on data reported on the End of Study case report form (CRF): If a subject terminated the study early during the Double-blind Dosing Period due to 'lack of therapeutic efficacy,' the subject was counted as a withdrawal due to treatment failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Allodynia at Week 15/EOT</measure>
    <time_frame>Week 15/EOT</time_frame>
    <description>Investigators rated subjects' allodynia as mild, moderate, severe, or not present. The presence of allodynia (yes/no) at Week 15/EOT was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period</measure>
    <time_frame>Baseline to Week 15</time_frame>
    <description>If acetaminophen was not reported on the Pain Therapy CRF or on the Concomitant Medication CRF, it was assumed that the subject did not use rescue analgesic medication.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel 6mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel 8mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, once daily, for 15 weeks (taken orally).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007 (2 mg)</intervention_name>
    <description>Perampanel, 2 mg once daily, for 15 weeks (taken orally).</description>
    <arm_group_label>Perampanel 2mg</arm_group_label>
    <other_name>Perampanel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007 (4 mg)</intervention_name>
    <description>Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).</description>
    <arm_group_label>Perampanel 4mg</arm_group_label>
    <other_name>Perampanel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007 (6 mg)</intervention_name>
    <description>Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).</description>
    <arm_group_label>Perampanel 6mg</arm_group_label>
    <other_name>Perampanel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007 (8 mg)</intervention_name>
    <description>Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).</description>
    <arm_group_label>Perampanel 8mg</arm_group_label>
    <other_name>Perampanel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        To be included, patients must meet all of the following:

          1. Provide written informed consent, prior to entering the study or undergoing any study
             procedures

          2. Male and female patients ≥18 years of age will be eligible for enrollment. Females
             should be either not of childbearing potential as a result of surgery or menopause (1
             year after onset), or of childbearing potential and practicing a medically acceptable
             method of contraception (e.g., abstinence, a barrier method plus spermicide, or
             intrauterine device [IUD]) for at least 1 month before Screening (Visit 1) and for 1
             month after the end of the study (Visit 8). They must also have a negative serum
             beta-human chorionic gonadotropin (ß-hCG) at Screening (Visit 1). Those females using
             hormonal contraceptives must also be using an additional approved method of
             contraception (e.g., a barrier method plus spermicide or IUD) starting with the
             Baseline Phase and continuing throughout the study period.

          3. Have Type I or Type II diabetes with painful, distal, symmetrical, sensory-motor
             neuropathy attributed to diabetes, of at least 12 months duration

          4. Have pain that has been stable over the past 6 months and, in the opinion of the
             investigator, not in an identifiably improving or worsening trend

          5. Have hemoglobin A1c ≤ 11%

          6. Score of ≥ 40 mm on the visual analog scale (VAS) of the short form McGill Pain
             Questionnaire (SF-MPQ) at both Screening (Visit 1) and Baseline (Visit 2 prior to
             randomization)

          7. Have completed the patient diary for at least 6 of the 7 days prior to Baseline (Visit
             2)

          8. Have average daily pain score of ≥ 4, on 11-point Likert-type numeric rating scale
             during the 7 days prior to Baseline (to be obtained from the patient diary)

          9. Be reliable, willing, and able to cooperate with all study procedures including the
             following:

               1. accurately fill out the diary on a daily basis

               2. return for study visits on the required dates

               3. accurately and reliably report symptoms (including treatment-emergent signs and
                  symptoms)

               4. take study drug as required by protocol

         10. Be on stable antidiabetic treatment (insulin, oral agents, or lifestyle) that is not
             anticipated to change during the course of the study, except if medically required

         11. Be on stable analgesic treatment (same medication and dose) or stable
             nonpharmacological pain treatment for at least 4 weeks prior to Screening (Visit 1)
             and remain on this stable treatment throughout the study (unless otherwise directed by
             a physician). Nonpharmacologic pain treatment includes the following:
             relaxation/hypnosis, physical or occupational therapy, counseling, etc. Episodic or
             periodic treatments such as monthly injections for treatment of pain (e.g., local
             anesthetics) will not be permitted.

        EXCLUSION CRITERIA:

        Patients with any one of the following will be excluded.

          1. Patients with any condition that could interfere with the conduct of the study or
             confound efficacy evaluations including the following:

               1. Pain or neuropathy from another cause (including central pain, radiculopathy,
                  painful arthritis, etc.)

               2. Skin or soft-tissue lesions in the area affected by neuropathy that are painful
                  or could alter sensation

               3. Amputation, other than toes

          2. Patients motivated by secondary gain, or where there is a negative-incentive to
             achieving pain and functional pain relief (eg, litigation). This will be determined by
             the patient's medical history.

          3. Patients with clinically significant, progressive, or potentially unstable disease of
             any body system including cardiovascular, gastrointestinal, CNS, psychiatric,
             endocrine (other than diabetes), or immunologic, including patients with any of the
             following broad disease categories:

               1. Systemic infections (e.g., human immunodeficiency virus [HIV], hepatitis,
                  tuberculosis [TB], syphilis)

               2. History of past (within the past 12 months) or present drug or alcohol abuse as
                  per the Diagnostic and Statistical Manual - 4th Edition (DSM IV) criteria

               3. History of acute coronary syndrome within the past 12 months

               4. Active cancer within the previous 5 years

               5. Systemic chemotherapy or immunotherapy within the past 5 years

               6. History of major depression, bipolar disease, psychosis or suicidal ideation or
                  attempts within the past 5 years

          4. Patients with any of the following laboratory abnormalities at Screening (Visit 1) or
             Baseline (Visit 2):

               1. Clinically significant electrocardiogram (ECG) abnormality, including prolonged
                  QTc (defined as QTc ≥ 450 msec)

               2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times
                  the upper limit of normal (ULN)

               3. White blood cell (WBC) count ≤ 2500/μL, absolute neutrophil count ≤ 1000/μL,
                  platelet count &lt; 100,000

               4. Positive urine drug screen for drugs of abuse, except those prescribed by a
                  properly licensed practitioner (e.g., opioids such as codeine for neuropathic
                  pain)

               5. Other clinically significant laboratory values

          5. Exposure to an investigational drug (including E2007) within the 30 days prior to
             Screening (Visit 1) or any prior exposure to E2007.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Laurenza, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Richard Blonsky</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>February 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2013</results_first_posted>
  <disposition_first_submitted>August 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2012</disposition_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Perampanel 2mg</title>
          <description>(Perampanel 2mg once daily for 15 weeks)</description>
        </group>
        <group group_id="P3">
          <title>Perampanel 4mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
        </group>
        <group group_id="P4">
          <title>Perampanel 6mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
        </group>
        <group group_id="P5">
          <title>Perampanel 8mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Perampanel 2mg</title>
          <description>(Perampanel 2mg once daily for 15 weeks)</description>
        </group>
        <group group_id="B3">
          <title>Perampanel 4mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
        </group>
        <group group_id="B4">
          <title>Perampanel 6mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
        </group>
        <group group_id="B5">
          <title>Perampanel 8mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="68"/>
            <count group_id="B6" value="345"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline characteristics look at Safety Population (subjects who were randomized, took at least 1 dose of study drug, and had at least 1 post-baseline assessment).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>This baseline characteristic is for Race.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)</title>
        <description>Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified baseline observation carried forward (BOCF).</description>
        <time_frame>Baseline to Week 15/EOT</time_frame>
        <population>Intent-to-Treat (ITT) Population - Randomized subjects who took at least 1 dose of study drug and had at least 1 efficacy assessment at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)</title>
          <description>Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified baseline observation carried forward (BOCF).</description>
          <population>Intent-to-Treat (ITT) Population - Randomized subjects who took at least 1 dose of study drug and had at least 1 efficacy assessment at Baseline.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="2.19"/>
                    <measurement group_id="O2" value="-1.73" spread="2.34"/>
                    <measurement group_id="O3" value="-1.30" spread="2.18"/>
                    <measurement group_id="O4" value="-1.85" spread="2.01"/>
                    <measurement group_id="O5" value="-1.18" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score</title>
        <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.</description>
        <time_frame>Baseline to Week 15/EOT</time_frame>
        <population>ITT Population. A responder was defined as a subject who had at least a 30% reduction in average pain scores from Baseline to Week 15/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score</title>
          <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.</description>
          <population>ITT Population. A responder was defined as a subject who had at least a 30% reduction in average pain scores from Baseline to Week 15/EOT.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="36.6"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="39.4"/>
                    <measurement group_id="O5" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="63.4"/>
                    <measurement group_id="O3" value="67.6"/>
                    <measurement group_id="O4" value="60.6"/>
                    <measurement group_id="O5" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 50% Reduction in Pain Score</title>
        <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.</description>
        <time_frame>Baseline to Week 15/EOT</time_frame>
        <population>ITT Population. A responder was defined as a subject who had at least a 50% reduction in average pain scores from Baseline to Week 15/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 50% Reduction in Pain Score</title>
          <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.</description>
          <population>ITT Population. A responder was defined as a subject who had at least a 50% reduction in average pain scores from Baseline to Week 15/EOT.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="22.1"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="76.1"/>
                    <measurement group_id="O3" value="77.9"/>
                    <measurement group_id="O4" value="69.7"/>
                    <measurement group_id="O5" value="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Average Pain Scores From Baseline at Each Study Week</title>
        <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Last on-treatment value refers to last 7 days of available diary data while subject was on double-blind study drug.</description>
        <time_frame>Baseline, Week 1 to Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Average Pain Scores From Baseline at Each Study Week</title>
          <description>Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Last on-treatment value refers to last 7 days of available diary data while subject was on double-blind study drug.</description>
          <population>ITT Population</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="1.46"/>
                    <measurement group_id="O2" value="-0.71" spread="1.33"/>
                    <measurement group_id="O3" value="-0.58" spread="1.39"/>
                    <measurement group_id="O4" value="-0.79" spread="1.44"/>
                    <measurement group_id="O5" value="-0.72" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="1.65"/>
                    <measurement group_id="O2" value="-1.09" spread="1.53"/>
                    <measurement group_id="O3" value="-0.80" spread="1.55"/>
                    <measurement group_id="O4" value="-1.19" spread="1.71"/>
                    <measurement group_id="O5" value="-1.05" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.85"/>
                    <measurement group_id="O2" value="-1.33" spread="1.64"/>
                    <measurement group_id="O3" value="-0.91" spread="1.67"/>
                    <measurement group_id="O4" value="-1.53" spread="1.92"/>
                    <measurement group_id="O5" value="-1.22" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.73"/>
                    <measurement group_id="O2" value="-1.33" spread="2.01"/>
                    <measurement group_id="O3" value="-1.10" spread="1.93"/>
                    <measurement group_id="O4" value="-1.75" spread="1.99"/>
                    <measurement group_id="O5" value="-1.38" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="1.71"/>
                    <measurement group_id="O2" value="-1.55" spread="2.21"/>
                    <measurement group_id="O3" value="-1.12" spread="2.08"/>
                    <measurement group_id="O4" value="-1.93" spread="1.96"/>
                    <measurement group_id="O5" value="-1.56" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="1.81"/>
                    <measurement group_id="O2" value="-1.70" spread="2.17"/>
                    <measurement group_id="O3" value="-1.31" spread="2.12"/>
                    <measurement group_id="O4" value="-2.03" spread="2.14"/>
                    <measurement group_id="O5" value="-1.58" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="1.96"/>
                    <measurement group_id="O2" value="-1.84" spread="2.10"/>
                    <measurement group_id="O3" value="-1.50" spread="2.04"/>
                    <measurement group_id="O4" value="-2.31" spread="2.32"/>
                    <measurement group_id="O5" value="-1.80" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="2.01"/>
                    <measurement group_id="O2" value="-1.86" spread="2.05"/>
                    <measurement group_id="O3" value="-1.72" spread="2.20"/>
                    <measurement group_id="O4" value="-2.19" spread="2.23"/>
                    <measurement group_id="O5" value="-1.71" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="2.10"/>
                    <measurement group_id="O2" value="-1.86" spread="2.14"/>
                    <measurement group_id="O3" value="-1.76" spread="2.19"/>
                    <measurement group_id="O4" value="-2.28" spread="2.12"/>
                    <measurement group_id="O5" value="-2.01" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="1.96"/>
                    <measurement group_id="O2" value="-1.88" spread="2.19"/>
                    <measurement group_id="O3" value="-1.84" spread="2.12"/>
                    <measurement group_id="O4" value="-2.04" spread="1.98"/>
                    <measurement group_id="O5" value="-1.92" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="2.03"/>
                    <measurement group_id="O2" value="-1.98" spread="2.20"/>
                    <measurement group_id="O3" value="-1.85" spread="2.14"/>
                    <measurement group_id="O4" value="-2.10" spread="2.09"/>
                    <measurement group_id="O5" value="-1.95" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="1.99"/>
                    <measurement group_id="O2" value="-1.81" spread="2.31"/>
                    <measurement group_id="O3" value="-1.76" spread="2.16"/>
                    <measurement group_id="O4" value="-2.13" spread="2.11"/>
                    <measurement group_id="O5" value="-1.91" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="2.00"/>
                    <measurement group_id="O2" value="-1.80" spread="2.16"/>
                    <measurement group_id="O3" value="-1.62" spread="2.29"/>
                    <measurement group_id="O4" value="-2.23" spread="1.99"/>
                    <measurement group_id="O5" value="-2.01" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="2.17"/>
                    <measurement group_id="O2" value="-1.84" spread="2.31"/>
                    <measurement group_id="O3" value="-1.56" spread="2.27"/>
                    <measurement group_id="O4" value="-2.25" spread="2.00"/>
                    <measurement group_id="O5" value="-1.89" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="2.23"/>
                    <measurement group_id="O2" value="-1.99" spread="2.39"/>
                    <measurement group_id="O3" value="-1.58" spread="2.16"/>
                    <measurement group_id="O4" value="-2.36" spread="1.91"/>
                    <measurement group_id="O5" value="-1.93" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.40" spread="2.38"/>
                    <measurement group_id="O2" value="-2.49" spread="2.20"/>
                    <measurement group_id="O3" value="-1.50" spread="2.12"/>
                    <measurement group_id="O4" value="-1.87" spread="2.12"/>
                    <measurement group_id="O5" value="-1.88" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data unavailable for some arms due to end of study.</measurement>
                    <measurement group_id="O2" value="-5.50" spread="3.33"/>
                    <measurement group_id="O3" value="NA">Data unavailable for some arms due to end of study.</measurement>
                    <measurement group_id="O4" value="NA">Data unavailable for some arms due to end of study.</measurement>
                    <measurement group_id="O5" value="0.71">Data unavailable for some arms due to end of study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last On-Treatment Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="2.18"/>
                    <measurement group_id="O2" value="-1.79" spread="2.32"/>
                    <measurement group_id="O3" value="-1.48" spread="2.23"/>
                    <measurement group_id="O4" value="-2.41" spread="2.15"/>
                    <measurement group_id="O5" value="-1.69" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Sleep Interference Scores From Baseline to Week 15/EOT</title>
        <description>Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for sleep interference (0=pain did not interfere with sleep, to 10=pain completely interfered with sleep [unable to sleep]). Based on modified BOCF.</description>
        <time_frame>Baseline to Week 15/EOT</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Sleep Interference Scores From Baseline to Week 15/EOT</title>
          <description>Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for sleep interference (0=pain did not interfere with sleep, to 10=pain completely interfered with sleep [unable to sleep]). Based on modified BOCF.</description>
          <population>ITT Population</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="2.18"/>
                    <measurement group_id="O2" value="-1.49" spread="2.11"/>
                    <measurement group_id="O3" value="-1.08" spread="2.19"/>
                    <measurement group_id="O4" value="-1.71" spread="2.00"/>
                    <measurement group_id="O5" value="-1.15" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form - McGill Pain Questionnaire (SF-MPQ) From Baseline to Week 15/EOT</title>
        <description>SF-MPQ sensory score = sum of intensity scores for descriptors 1-11 (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting). Each descriptor scored as 0=none, 1=mild, 2=moderate, or 3=severe. Range of possible sensory scores, 0 to 33, with a score of 33 being the most severe intensity.</description>
        <time_frame>Baseline and Week 15/EOT</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form - McGill Pain Questionnaire (SF-MPQ) From Baseline to Week 15/EOT</title>
          <description>SF-MPQ sensory score = sum of intensity scores for descriptors 1-11 (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting). Each descriptor scored as 0=none, 1=mild, 2=moderate, or 3=severe. Range of possible sensory scores, 0 to 33, with a score of 33 being the most severe intensity.</description>
          <population>ITT Population</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="6.83"/>
                    <measurement group_id="O2" value="-3.9" spread="6.93"/>
                    <measurement group_id="O3" value="-4.8" spread="5.83"/>
                    <measurement group_id="O4" value="-6.2" spread="6.91"/>
                    <measurement group_id="O5" value="-2.9" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Patient Global Impression of Change (PGIC) at Week 15/EOT</title>
        <description>At the EOT (Visit 7) or Early Withdrawal Visit (as appropriate), the subject assessed his/her status compared to how they felt before entering the study. This assessment included an evaluation of pain frequency and intensity, the occurrence of AEs, and overall functional status using a 7-point scale where 1=very much improved and 7=very much worse. Using Modified BOCF.</description>
        <time_frame>Week 15/EOT</time_frame>
        <population>Subset of ITT population used, including subjects that completed PGIC at Week 15 visit, and using BOCF (baseline observation carried forward) subjects that terminated prior to Week 15 received a 'No Change' if due to AE or Lack of Therapeutic Efficacy, subjects who discontinued due to other reasons used PGIC scores from Early Termination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Patient Global Impression of Change (PGIC) at Week 15/EOT</title>
          <description>At the EOT (Visit 7) or Early Withdrawal Visit (as appropriate), the subject assessed his/her status compared to how they felt before entering the study. This assessment included an evaluation of pain frequency and intensity, the occurrence of AEs, and overall functional status using a 7-point scale where 1=very much improved and 7=very much worse. Using Modified BOCF.</description>
          <population>Subset of ITT population used, including subjects that completed PGIC at Week 15 visit, and using BOCF (baseline observation carried forward) subjects that terminated prior to Week 15 received a 'No Change' if due to AE or Lack of Therapeutic Efficacy, subjects who discontinued due to other reasons used PGIC scores from Early Termination visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 15/EOT in SF-36 Physical and Mental Component Scores</title>
        <description>Short Form 36 Health Survey Questionnaire (SF-36) measuring limitations in Physical Components including physical activities, usual role activities (due to physical problems), measuring bodily pain, general health perceptions, and Mental Components including social activities, usual role activities (due to emotional problems), vitality (energy and fatigue. Each of the 8 domains are described by a score ranging from 0 to 100, for a range of total possible scores of 0-400 for physical and 0-400 for mental. Higher scores reflect better subject status.</description>
        <time_frame>Baseline and Week 15/EOT</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 15/EOT in SF-36 Physical and Mental Component Scores</title>
          <description>Short Form 36 Health Survey Questionnaire (SF-36) measuring limitations in Physical Components including physical activities, usual role activities (due to physical problems), measuring bodily pain, general health perceptions, and Mental Components including social activities, usual role activities (due to emotional problems), vitality (energy and fatigue. Each of the 8 domains are described by a score ranging from 0 to 100, for a range of total possible scores of 0-400 for physical and 0-400 for mental. Higher scores reflect better subject status.</description>
          <population>ITT Population</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="7.43"/>
                    <measurement group_id="O2" value="1.57" spread="6.35"/>
                    <measurement group_id="O3" value="1.67" spread="8.21"/>
                    <measurement group_id="O4" value="1.59" spread="7.92"/>
                    <measurement group_id="O5" value="0.89" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="9.14"/>
                    <measurement group_id="O2" value="0.40" spread="8.26"/>
                    <measurement group_id="O3" value="0.06" spread="10.77"/>
                    <measurement group_id="O4" value="-1.90" spread="8.74"/>
                    <measurement group_id="O5" value="-1.61" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 15/EOT in Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression Subscale Scores</title>
        <description>HADS anxiety subscale score=sum of scores for 7 anxiety items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse anxiety. Range of possible HADS anxiety subscale scores, 0 to 21. HADS depression subscale score=sum of scores for 7 depression items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse depression. Range of possible HADS depression subscale scores, 0 to 21.</description>
        <time_frame>Baseline and Week 15/EOT</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 15/EOT in Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression Subscale Scores</title>
          <description>HADS anxiety subscale score=sum of scores for 7 anxiety items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse anxiety. Range of possible HADS anxiety subscale scores, 0 to 21. HADS depression subscale score=sum of scores for 7 depression items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse depression. Range of possible HADS depression subscale scores, 0 to 21.</description>
          <population>ITT Population</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.01"/>
                    <measurement group_id="O2" value="-0.3" spread="2.85"/>
                    <measurement group_id="O3" value="-0.5" spread="3.43"/>
                    <measurement group_id="O4" value="-0.5" spread="2.89"/>
                    <measurement group_id="O5" value="-0.4" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.72"/>
                    <measurement group_id="O2" value="-0.4" spread="2.43"/>
                    <measurement group_id="O3" value="0.0" spread="3.16"/>
                    <measurement group_id="O4" value="0.1" spread="3.42"/>
                    <measurement group_id="O5" value="0.2" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal Due to Treatment Failure During Double-Blind Dosing Period</title>
        <description>Based on data reported on the End of Study case report form (CRF): If a subject terminated the study early during the Double-blind Dosing Period due to ‘lack of therapeutic efficacy,’ the subject was counted as a withdrawal due to treatment failure.</description>
        <time_frame>Baseline and Week 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal Due to Treatment Failure During Double-Blind Dosing Period</title>
          <description>Based on data reported on the End of Study case report form (CRF): If a subject terminated the study early during the Double-blind Dosing Period due to ‘lack of therapeutic efficacy,’ the subject was counted as a withdrawal due to treatment failure.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (withdrawn)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Not withdrawn)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Allodynia at Week 15/EOT</title>
        <description>Investigators rated subjects’ allodynia as mild, moderate, severe, or not present. The presence of allodynia (yes/no) at Week 15/EOT was analyzed.</description>
        <time_frame>Week 15/EOT</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Allodynia at Week 15/EOT</title>
          <description>Investigators rated subjects’ allodynia as mild, moderate, severe, or not present. The presence of allodynia (yes/no) at Week 15/EOT was analyzed.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Allodynia present)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Allodynia absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period</title>
        <description>If acetaminophen was not reported on the Pain Therapy CRF or on the Concomitant Medication CRF, it was assumed that the subject did not use rescue analgesic medication.</description>
        <time_frame>Baseline to Week 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Perampanel 2mg</title>
            <description>(Perampanel 2mg once daily for 15 weeks)</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 4mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 6mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Perampanel 8mg</title>
            <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period</title>
          <description>If acetaminophen was not reported on the Pain Therapy CRF or on the Concomitant Medication CRF, it was assumed that the subject did not use rescue analgesic medication.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Used rescue analgesic medication)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Did not use rescue analgesic medication)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs): started on or after (or before if TEAE worsened in severity after first dose) the day of first dose of double-blind study drug up to 30 days after the last dose of double-blind study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Perampanel 2mg</title>
          <description>(Perampanel 2mg once daily for 15 weeks)</description>
        </group>
        <group group_id="E3">
          <title>Perampanel 4mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks, followed by perampanel 4mg once daily for 12 weeks)</description>
        </group>
        <group group_id="E4">
          <title>Perampanel 6mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks; followed by perampanel 4mg once daily for 3 weeks; and finally, perampanel 6mg once daily for 9 weeks)</description>
        </group>
        <group group_id="E5">
          <title>Perampanel 8mg</title>
          <description>(Perampanel 2mg once daily for 3 weeks; then, perampanel 4mg once daily for 3 weeks; followed by perampanel 6mg once daily for 3 weeks; and finally, perampanel 8mg once daily for 6 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v. 10.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Escherichia Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Wound Infection Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Systolic Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Blood Pressure Fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Homocidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v. 10.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Inc.</name_or_title>
      <organization>Eisai Call Center</organization>
      <phone>888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

